Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

The Bristol-Myers Squibb announced a quarterly dividend

3/3/23 BMY

Magnit will expand the MCosmetic chain in Uzbekistan

3/3/23 MGNT

Broadcom reported for Q1 FY2023

3/3/23 AVGO

Profit of Central Telegraph in 2022 decreased by more than 40 times

3/3/23 CNTL

Segezha Group considers Egypt the most likely place for the new plant

3/3/23 SGZH

MGTS reported for 2022 according to IFRS

3/3/23 MGTS

RusHydro's IFRS profit in 2022 halved

3/3/23 HYDR

The number of open accounts at Mosbirzha has exceeded 24 million

3/3/23 MOEX

MTS net profit in 2022 decreased by almost 50%

3/3/23 MTSS

PhosAgro's net profit in 2022 increased by more than 40%

3/3/23 PHOR